

Clinical Trial Protocol

Iranian Registry of Clinical Trials

09 Jun 2026

In local healthy human volunteers after single subcutaneous dose of 20 kDa peginterferon α -2a (from Unipeg \square) evaluation of safety and pharmacokinetics of the drug

Protocol summary

Summary

Study Title: Pharmacokinetic and Safety evaluation of pegylated interferon α -2a from its commercial product "Unipeg \square " in healthy human subjects. Study goal: To establish the Pharmacokinetic and safety of 20 kDa peginterferon (Unipeg \square) in Pakistani population. Study Design: Open label, single period, single treatment, and single dose study in healthy volunteers. Sample size: Ten Inclusion Criteria: Healthy male subjects, Age: 18-45 years, BMI: 18-26 kg/m², Able to understand and give free written informed consent, Non-smoker, non-alcoholic Exclusion criteria: any illness, blood donation in last two months, OTC and any prescription drug in last 14 and 30 days respectively. Participation in another study within last 2 months Treatments: After 10 hour fasting; single dose of PEG-interferon alfa-2a 180mcg administered subcutaneously in the morning in abdominal region. 5ml blood was collected at 0, 1, 2, 3, 6, 12, 24, 36, 60, 84, 108, 132, & 156 hours after drug administration. Safety: through physical examination, vital sign, adverse events and lab test monitoring on screening, fifth day and at follow up after two weeks. CBC and ALT test for safety on day five and sixteen. Analysis: through ELISA Pharmacokinetics analysis: PK Parameters; AUC_{0-t}, AUC_{0- ∞} , C_{max}, T_{max} and T_{1/2}. determined by model independent method using PK-solution and PP-stat software Ethical consideration: Approved from independent ethics committee of ICCBS, University of Karachi, and full compliance to Declaration of Helsinki and ICH-GCP.

General information

Acronym

IRCT registration information

IRCT registration number: **IRCT201111027978N1**
Registration date: **2012-02-11, 1390/11/22**

Registration timing: **retrospective**

Last update:

Update count: **0**

Registration date

2012-02-11, 1390/11/22

Registrant information

Name

Tasneem Ahmad

Name of organization / entity

Pharma Professional Services, Karachi, Pakistan

Country

Pakistan

Phone

(92-21) 34972358, 34820573

Email address

tasneem.ahmed@iccs.edu

Recruitment status

Recruitment complete

Funding source

Getz Pharma (Pvt) Ltd; Karachi, Pakistan

Expected recruitment start date

2010-07-21, 1389/04/30

Expected recruitment end date

2010-08-05, 1389/05/14

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

In local healthy human volunteers after single subcutaneous dose of 20 kDa peginterferon α -2a (from Unipeg \square) evaluation of safety and pharmacokinetics of

the drug

Public title

A STUDY OF UNIPEG® IN HEALTHY HUMAN SUBJECTS TO EVALUATE ITS SAFETY AND PHARMACOKINETIC BEHAVIOUR

Purpose

Other

Inclusion/Exclusion criteria

INCLUSION: Healthy human volunteers, BMI: 18-26 Kg/m², non-smoker, non-alcoholic, with normal lab reports for CBC, LFT, HBsAg, Anti HCV, HIV antibody
EXCLUSION: • Any active allergic disease or a history of significant allergic disease. • Presence of renal, hepatic or gastrointestinal disease known to interfere with the drug absorption, distribution, metabolism or elimination with in last year. • Subject demonstrates protocol non-compliance (e.g. uncooperative attitude, & inability to finish study). • Participation in another study within last 2 months of 1st drug administration. • If donated blood within last 2 months preceding the study. • Age below 18 years and above 45yr. • Smoking within last 3 months prior to the drug administration and 6 hours after drug administration. • Ingestion of OTC drug (except Paracetamol) within last 14 days of 1st drug administration. • Participants with insufficient organ and/or bone marrow dysfunction. • Ingestion of investigational drug within 1 year prior to 1st drug administration. • Participants with low blood counts and hematology results outside the normal range. (ANC) absolute neutrophil count should be > 1500/mm³ and platelet count should be greater than 50,000/ mm³. • Participants with an uncontrolled medical condition (i.e., hypertension, cardiac arrhythmias, CHF) that places the patient at risk by participating in the study. • Participants with any physical/mental disability • Subjects with known HIV, hepatitis B or hepatitis C infection, or autoimmune diseases. • History of major organ transplantation, new onset diabetes, unstable thyroid function. • Concurrent therapy with immunosuppressive drugs or cytotoxic agents. • Alcohol or drug abuse within the past year. • Known hypersensitivity to investigational drug • Participants with uncontrolled brain metastases or central nervous system disease. • Strenuous physical activity performed within 48 hours before drug administration and during study. • Positive drug of abuse test and alcohol test. • Intake of gutka, pan and any other thing containing nicotine 48 hours before and during study. • Volunteer with thyroid dysfunction.

Age

From **18 years** old to **45 years** old

Gender

Male

Phase

4

Groups that have been masked

No information

Sample size

Target sample size: **10**

Randomization (investigator's opinion)

N/A

Randomization description

Blinding (investigator's opinion)

Not blinded

Blinding description

Placebo

Not used

Assignment

Single

Other design features

Secondary Ids

1

Registry name

Iranian Registry of Clinical Trials (IRCT)

Secondary trial Id

CB-002-PEG-2010

Registration date

2012-01-16, 1390/10/26

Ethics committees

1

Ethics committee

Name of ethics committee

Independent Ethics Committee of International Center for Chemical and Biological Sciences (ICCBS); P

Street address

University of Karachi

City

Karachi

Postal code

75270

Approval date

2010-07-09, 1389/04/18

Ethics committee reference number

ICCBS/IEC/Lett-17/10

Health conditions studied

1

Description of health condition studied

Chronic viral hepatitis C

ICD-10 code

B18.2

ICD-10 code description

Viral Hepatitis

Primary outcomes

1

Description

Serum levels of peginterferon α -2a Pharmacokinetic parameters: C_{max}, T_{max}, AUC_{0-t}, AUC_{0-∞}, T_{1/2},

Timepoint

At 0, 1, 2, 3, 6, 12, 24, 36, 60, 84, 108, 132 and 156 hours

Method of measurement

• Serum concentration measured by Enzyme-linked immunosorbent assay (ELISA). • Pharmacokinetic (PK) parameter will be determined on the basis of measurement of concentration; performed by means of model independent method using Pk-solution and PPstat computer programs. • Elimination half-life (T1/2) calculated as 0.693 /k. • Area under the curve to the last measurable concentration (AUC) 0-t) will be calculated by the linear trapezoidal rule. Area under the curve extrapolated to infinity (AUC_{0-∞}) will be calculated as AUC_{0-t} + C_t /k, where C_t is the last measurable concentration.

Secondary outcomes

1

Description

Safety as measured by the frequency and intensity of adverse events (AEs), vital signs measurement, Lab tests: effect on neutrophils, total leukocytes count, absolute neutrophil counts, Hb levels, ALT levels.

Timepoint

Adverse events Monitoring: throughout study period (two weeks) Vital sign measurement: at time 0, 1, 2, 4, 8, 12, 24, 36, 60, 84, 108, 132, & 156hours. 0 to 156 hours Lab tests: within two weeks before drug administration (Baseline), on day five (during study) and day sixteen of drug administration (at follow up visit)

Method of measurement

By measuring the frequency and intensity of Standard Pharmacokinetic analysis of Serum level profile adverse event. For lab tests: comparing the day five and sixteen results with baseline results and calculated the p-value at 5% level of significance.

Intervention groups

1

Description

Peginterferon α-2a; 180 µg single dose; subcutaneously in abdominal region.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Center for Bioequivalence Studies and Bioassay Research

Full name of responsible person

Prof. Dr. Tasneem Ahmad

Street address

CBSBR at ICCBS University of Karachi

City

Karachi

Sponsors / Funding sources

1

Sponsor

Name of organization / entity

Getz Pharma (Pvt) Limited

Full name of responsible person

Dr. Khawar Mehdi

Street address

Director Medical Affairs, 29-30, Secotr-27, Korangi Industrial Area

City

Karachi

Grant name

Grant code / Reference number

Is the source of funding the same sponsor organization/entity?

Yes

Title of funding source

Getz Pharma (Pvt) Limited

Proportion provided by this source

100

Public or private sector

empty

Domestic or foreign origin

empty

Category of foreign source of funding

empty

Country of origin

Type of organization providing the funding

empty

Person responsible for general inquiries

Contact

Name of organization / entity

Pharma Professional Services, Karachi, Pakistan

Full name of responsible person

Ms. Ghousia Saba

Position

Manager Clinical Services/ B.Pharm

Other areas of specialty/work

Street address

8 Gulshan View, Gulshan-e-Iqbal, Karachi,

City

Karachi

Province

Sind

Postal code

75300

Phone

009221-34972358

Fax

Email

ghousia@phaps.com

Web page address

www.phaps.com

Person responsible for scientific

inquiries

Contact

Name of organization / entity

Center for Bioequivalence Studies and Bioassay
Research (CBSBR), International Center for Chemical
a

Full name of responsible person

Prof. Dr. Tasneem Ahmad

Position

Ph.D.

Other areas of specialty/work

Street address

CBSBR at ICCBS, University of Karachi

City

Karachi

Province

Sind

Postal code

75300

Phone

009221-111222292

Fax

Email

tasneem.ahmed@iccs.edu

Web page address

www.iccs.edu

Person responsible for updating data

Contact

Name of organization / entity

Pharma Professional Services, Karachi, Pakistan

Full name of responsible person

Ms. Ghouisia Saba

Position

Manager Clinical Services/ B.Pharm

Other areas of specialty/work

Street address

8 Gulshan View, Gulshan-e-Iqbal, Karachi,

City

Karachi

Province

-Sind

Postal code

75300

Phone

00922134972358

Fax

Email

ghousia@phaps.com

Web page address

www.phaps.com

Sharing plan

Deidentified Individual Participant Data Set (IPD)

empty

Study Protocol

empty

Statistical Analysis Plan

empty

Informed Consent Form

empty

Clinical Study Report

empty

Analytic Code

empty

Data Dictionary

empty